ResMed Inc (STU:RME)
€ 232.3 -1.9 (-0.81%) Market Cap: 34.52 Bil Enterprise Value: 34.92 Bil PE Ratio: 32.70 PB Ratio: 6.98 GF Score: 98/100

Resmed Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript

Jan 06, 2022 / 09:00PM GMT
Release Date Price: €213.3 (-4.56%)
Chris Cooper
Goldman Sachs Group, Inc., Research Division - Research Analyst

Okay. Welcome back, everyone to the 14th Annual Healthcare CEOs Unscripted Conference. For those that don't know me, my name is Chris Cooper. I'm the healthcare analyst here at Goldman Sachs in Australia. For the next session, we are very fortunate to be joined by Mick Farrell, the CEO of ResMed. In a moment, I'll invite Mick to make a couple of minutes of introductory comments about himself and the company.

And then after that, the format of the session is going to be very informal. It's unscripted. We will -- we have 60 minutes or so for the session. If you do have any specific questions you'd like us to cover during the course of the session, please just e-mail me directly, and I'll try my best to weave in those questions into the discussion as we go. My e-mail is [email protected]. And without further ado, I'll hand over to Mick for some introductory comments. Thanks very much.

Michael J. Farrell
ResMed Inc. - CEO & Director

Well, thanks, Chris, and great to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot